Zetia has just recovered the position of Merck & Co as Shares of Merck & Co have been raised by 2 percent, were dropped down after the results of a research released on Annual meeting of American Heart Association in Florida on last Sunday. On the very next day New England Journal of Medicine has published an editorial which revealed that the trail study carried out named ARBITER 6 wasn’t enough to rely on. The sample size was very small hence the reports were terminated on the basis of its prematurity and the small number of patients.

This statement and discussion managed to bring back 2 % value of Merck & Co, which it lost in the trading right after the release of the trial study.

The study revealed that the Abbott’s Product Niaspan is more efficient and helpful than Zetia to minimize the thickness of the arty walls. The trail study was presented and it showed that Zetia had no effect whatsoever on the blood vassal walls but the Niaspan helped in decreasing the thickness of walls of arties significantly.

The report released was based on few numbers of patients and doctors did appreciated but they were not convinced with the size of the trail study.

It has been researched that the thickness of the arty walls disturbs the blood circulation to the brain and it can be the reason for the heart diseases like Heart attacks or heart stokes.

The Researcher suggested that the ARBITER 6 must be carried out on a large number of patients to provide the authentic and mature results.

Zetia